Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations

• Published in: Communications biology 2018-06, Vol.1 (1), p.70-70, Article 70
• Main Authors: Hauser, Kevin, Negron, Christopher, Albanese, Steven K., Ray, Soumya, Steinbrecher, Thomas, Abel, Robert, Chodera, John D., Wang, Lingle
• Format: Article
• Language: English
• Subjects: 631/114; 631/114/2413; 692/4028; Accuracy; Affinity; Biology; Biomedical and Life Sciences; Chronic myeloid leukemia; Enzyme inhibitors; Free energy; Kinases; Leukemia; Life Sciences; Missense mutation; Mutation; Myeloid leukemia; Therapeutic applications
• ISSN: 2399-3642; 2399-3642
• DOI: 10.1038/s42003-018-0075-x

The therapeutic effect of targeted kinase inhibitors can be significantly reduced by intrinsic or acquired resistance mutations that modulate the affinity of the drug for the kinase. In cancer, the majority of missense mutations are rare, making it difficult to predict their impact on inhibitor affinity. We examine the potential for alchemical free-energy calculations to predict how kinase mutations modulate inhibitor affinities to Abl, a major target in chronic myelogenous leukemia (CML). These calculations have useful accuracy in predicting resistance for eight FDA-approved kinase inhibitors across 144 clinically identified point mutations, with a root mean square error in binding free-energy changes of 1 . 1 0.9 1.3 kcal mol −1 (95% confidence interval) and correctly classifying mutations as resistant or susceptible with 8 8 82 93 % accuracy. This benchmark establishes the potential for physical modeling to collaboratively support the assessment and anticipation of patient mutations to affect drug potency in clinical applications. Kevin Hauser et al. accurately predict the impact of mutations in a kinase on the binding affinities of targeted kinase inhibitors using alchemical free-energy calculations. With 88% accuracy, resistance or sensitivity to therapy is computed for 144 clinically-identified point mutations in this major target in chronic myelogenous leukemia.